Ritlecitinib mainly targets JAK3, a direct downstream molecule of CD132, and has shown promising results in autoimmune diseases such as IBD, pemphigus, and vitiligo,44–46 indicating potential applications for 2D4. The gene discussed is JAK3; the disease is inflammatory bowel disease.